An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.

NCT00199381 Phase 3 TERMINATED Results posted

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

Details

Lead sponsor	Kyowa Kirin, Inc.
Phase	Phase 3
Status	TERMINATED
Enrolment	504
Start date	2005-10
Completion	2008-10

Conditions

• Parkinson's Disease

Interventions

• Istradefylline

Primary outcomes

• Safety as Measured by Adverse Events — Every 2 months up to 32 months
  Investigation of the long-term tolerability and safety of istradefylline

Countries

United States